Categories Earnings, Health Care
Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot
— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected.
— Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion.
— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.
— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.
— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.
— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.
Most Popular
DAL Earnings: All you need to know about Delta Air Lines’ Q1 2025 earnings results
Delta Air Lines (NYSE: DAL) reported its first quarter 2025 earnings results today. Operating revenue increased 2% year-over-year to $14 billion. Net income was $240 million, or $0.37 per share,
Deals and R&D in focus as Johnson & Johnson gears up for Q1 earnings
For Johnson & Johnson (NYSE: JNJ), investments in its pipeline and exiting lower priority businesses remain central to its strategy in the new fiscal year. The healthcare behemoth is in
Earnings preview: What to expect when these major banks report Q1 2025 results
The leading players in the banking industry are set to report their earnings results for the first quarter of 2025 over this week and the next. While majors JPMorgan Chase
